Fundraising Fox

Immunitas Therapeutics

Waltham, US · Founded 2019 · Delaware corporation · 9 known investors

immunitastx.com ↗

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.

BiotechDigital HealthMedical Devicesin /immunitas

Founders & leadership

LB

Laura BrassDirector

AW

Amanda WagnerExecutive Officer

KW

Kai WucherpfennigDirector

DM

Dan MatloffExecutive Officer

JG

Jiaping GuDirector

JG

Jeffrey GoldbergExecutive Officer, Director

JE

Juergen EckhardtDirector

CW

Christoph WestphalDirector

LI

Lucio IannoneDirector

Investors · 9

DC Investment PartnersMcLean · $10M

Longwood FundBostonvia Christoph Westphal · board

Medical Excellence CapitalNew York

Novartis Venture FundBasel · $5M – $25M

Ono Venture Investment, Inc.South San Francisco

Solasta VenturesBoston

Agent Capitalreported · 2 sourcesWaltham

Leaps by BayerreportedLeverkusen

M Venturesreported · 2 sourcesLos Angeles · $10.8M

Reported raises · per SEC filings

Form D private placements

▶$29.1MraisedAug 2021 · 21 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Laura BrassDirector
Amanda WagnerExecutive Officer
Kai WucherpfennigDirector
Dan MatloffExecutive Officer
Jiaping GuDirector
Jeffrey GoldbergExecutive Officer, Director
Juergen EckhardtDirector
Christoph WestphalDirector
Lucio IannoneDirector

Offering amount: $57.7M
Amount sold: $29.1M
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news